Reverse Remodeling of the Pulmonary Vasculature: a Longitudinal, Investigational Study of the Effects of Sotatercept.

The goal of this study is to learn more about how sotatercept works and if it helps the lung arteries become healthier. Sotatercept will be associated with the following: 1. Improvement in capillary blush, reduce the tapering and tortuosity of affected vessels on pulmonary wedge angiography and decreased wall thickness on intravascular ultrasound in previously affected areas. 2. Improvement in previously poorly or non-perfused areas rather than increased perfusion to previously perfused areas. 3. No changes in baseline ventilation and improvement and ventilation/perfusion matching.

NCT Number	NCT07487441
Lead Sponsor	Franz Rischard, DO Collaborators: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Conditions	Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension
Enrollment	30 participants
Start Date	2026-03-15
Primary Completion	2028-03-15 (estimated)
Study Completion	2028-06-15 (estimated)
Updated on ClinicalTrials.gov	2026-03-23